Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Trenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Aptevo Therapeutics; Emergent BioSolutions; Inspiration Biopharmaceuticals
- 05 Jun 2017 Status changed from active, no longer recruiting to completed.
- 13 Dec 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017.
- 17 Sep 2014 New trial record